华大基因收盘下跌1.31%，最新市净率2.41，总市值219.47亿元

Core Viewpoint - BGI Genomics reported a decline in revenue and net profit for Q1 2025, indicating challenges in the current market environment [3] Group 1: Company Overview - BGI Genomics specializes in gene testing, mass spectrometry, bioinformatics analysis, and medical AI models, providing comprehensive solutions for research institutions, enterprises, medical organizations, and public health entities [2] - The company's main products include services for reproductive health research and clinical applications, cancer and chronic disease prevention, infection control research, multi-omics big data services, and precision medicine testing solutions [2] Group 2: Financial Performance - For Q1 2025, BGI Genomics achieved a revenue of 672 million yuan, representing a year-on-year decrease of 18.18% [3] - The net profit for the same period was -52.7 million yuan, reflecting a significant decline of 524.87% compared to the previous year [3] - The gross profit margin stood at 43.55% [3] Group 3: Market Position and Valuation - As of May 21, BGI Genomics' stock closed at 52.78 yuan, down 1.31%, with a latest price-to-book ratio of 2.41 and a total market capitalization of 21.947 billion yuan [1] - The company’s PE (TTM) ratio is -22.68, while the industry average is 49.38, indicating a significant divergence from industry peers [3]